Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...

Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...